20190718 – TRANSGENE PR MHRA TG6002
Month: July 2019
Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
20190710 PR MHRA TG4050 EN
Success of Transgene’s €48.7 Million Rights Issue
http://finance.transgene.fr/en/launch.php